Urinary Retention and Post-Void Residual Urine in Men: Separating Truth From Tradition

Journal of Urology

Volumn 180, Issue 1, 2008, Pages 47-54

  Kaplan, Steven A ^b   Wein, Alan J ^c   Staskin, David R ^a,b   Roehrborn, Claus G ^d   Steers, William D ^e  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

bladder; male; muscarinic antagonists; prostate; urinary retention

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; INDORAMIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

AGE DISTRIBUTION; BLADDER CATHETERIZATION; BLADDER NECK STENOSIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DETRUSOR DYSSYNERGIA; EPIDEMIOLOGICAL DATA; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MONOTHERAPY; NEUROGENIC BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; REVIEW; RISK FACTOR; URINE RETENTION; URODYNAMICS;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; URINARY RETENTION; URINATION; URINE;

EID: 44649084913     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.03.027     Document Type: Review

References (55)

1. Gleave J.R., and MacFarlane R. Prognosis for recovery of bladder function following lumbar central disc prolapse. Br J Neurosurg 4 (1990) 205
2. Sakakibara R., Hattori T., Yasuda K., and Yamanishi T. Micturitional disturbance in acute disseminated encephalomyelitis (ADEM). J Auton Nerv Syst 60 (1996) 200
3. Gallien P., Reymann J.M., Amarenco G., Nicolas B., de Seze M., and Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76 (2005) 1670
4. Sakakibara R., Uchiyama T., Liu Z., Yamamoto T., Ito T., Uzawa A., et al. Meningitis-retention syndrome. An unrecognized clinical condition. J Neurol 252 (2005) 1495
5. Drake M.J., Nixon P.M., and Crew J.P. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf 19 (1998) 45
6. Cespedes R.D. Treatment options for outlet obstruction following anti-incontinence surgery in females. Tech Urol 7 (2001) 118
7. Cross C.A., Cespedes R.D., English S.F., and McGuire E.J. Transvaginal urethrolysis for urethral obstruction after anti-incontinence surgery. J Urol 159 (1998) 1199
8. Thomas A.W., Cannon A., Bartlett E., Ellis-Jones J., and Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 93 (2004) 745
9. Abarbanel J., and Marcus E.L. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology 69 (2007) 436
10. Fitzpatrick J.M., and Kirby R.S. Management of acute urinary retention. BJU Int 97 suppl. (2006) 16
11. Roehrborn C.G., Bruskewitz R., Nickel G.C., Glickman S., Cox C., Anderson R., et al., The PLESS Study Group. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. Eur Urol 37 (2000) 528
12. Abrams P.H., Dunn M., and George N. Urodynamic findings in chronic retention of urine and their relevance to results of surgery. Br Med J 2 (1978) 1258
13. Neal D.E., Styles R.A., Powell P.H., and Ramsden P.D. Relationship between detrusor function and residual urine in men undergoing prostatectomy. Br J Urol 60 (1987) 560
14. Neal D.E., Styles R.A., Powell P.H., Thong J., and Ramsden P.D. Relationship between voiding pressures, symptoms and urodynamic findings in 253 men undergoing prostatectomy. Br J Urol 60 (1987) 554
15. Ghalayini I.F., Al-Ghazo M.A., and Pickard R.S. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention. BJU Int 96 (2005) 93
16. Taylor III J.A., and Kuchel G.A. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 54 (2006) 1920
17. Verhamme K.M., Dieleman J.P., van Wijk M.A., Bosch J.L., Stricker B.H., and Sturkenboom M.C. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 47 (2005) 494
18. Jacobsen S.J., Jacobson D.J., Girman C.J., Roberts R.O., Rhodes T., Guess H.A., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481
19. Meigs J.B., Barry M.J., Giovannucci E., Rimm E.B., Stampfer M.J., and Kawachi I. Incidence rates and risk factors for acute urinary retention: the Health Professionals Followup Study. J Urol 162 (1999) 376
20. Cathcart P., van derMeulen J., Armitage J., and Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 176 (2006) 200
21. Marberger M.J., and PROWESS Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology 51 (1998) 677
22. Nickel J.C., and Canadian PROSPECT Study Group. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Br J Urol 81 (1998) 383
23. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
24. Debruyne F., Barkin J., van Erps P., Reis M., Tammela T.L., Roehrborn C., et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488
25. Roberts R.O., Lieber M.M., Jacobson D.J., Girman C.J., and Jacobsen S.J. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 80 (2005) 759
26. Tubaro A., Carter S., Trucchi A., Punzo G., Petta S., and Miano L. Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage. Drugs Aging 20 (2003) 185
27. Ciancio S.J., Mutchnik S.E., Rivera V.M., and Boone T.B. Urodynamic pattern changes in multiple sclerosis. Urology 57 (2001) 239
28. Roehrborn C.G. Definition of at-risk patients: baseline variables. BJU Int 97 suppl. (2006) 7
29. Roehrborn C.G., Kaplan S.A., Lee M.W., Slawin K.M., McVary K.T., Kusek J.W., et al. Baseline post void residual urine volume as a predictor of urinary outcomes in men with BPH in the MTOPS study. J Urol 173 suppl. (2005) 443 abstract 1638
30. Roehrborn C.G., Bruskewitz R., Nickel J.C., McConnell J.D., Saltzman B., Gittelman M.C., et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171 (2004) 1194
31. Logie J., Clifford G.M., and Farmer R.D. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 95 (2005) 557
32. Klarskov P., Andersen J.T., Asmussen C.F., Brenoe J., Jensen S.K., Jensen I.L., et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. Scand J Urol Nephrol 21 (1987) 23
33. Roehrborn C.G., Malice M., Cook T.J., and Girman C.J. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58 (2001) 210
34. Roehrborn C.G., McConnell J.D., Lieber M., Kaplan S., Geller J., Malek G.H., et al., PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53 (1999) 473
35. Roehrborn C.G., McConnell J.D., Saltzman B., Bergner D., Gray T., Narayan P., et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 42 (2002) 1
36. Roehrborn C.G., Kaplan S.A., Noble W.D., Lucia M.S., Slawin K.M., McVary K.T., et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol 173 suppl. (2005) 346 abstract 1277
37. Kefi A., Koseoglu H., Celebi I., Yorukoglu K., and Esen A. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol 40 (2006) 155
38. Roehrborn C.G., Boyle P., Gould A.L., and Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581
39. Marberger M.J., Andersen J.T., Nickel J.C., Malice M.P., Gabriel M., Pappas F., et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 38 (2000) 563
40. Crawford E.D., Wilson S.S., McConnell J.D., Slawin K.M., Lieber M.C., Smith J.A., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422
41. Kaplan S., Garvin D., Gilhooly P., Koppel M., Labasky R., Milsten R., et al., The PLESS Study Group. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology 56 (2000) 610
42. Mochtar C.A., Kiemeney L.A., van Riemsdijk M.M., Laguna M.P., Debruyne F.M., and de laRosette J.J. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol 175 (2006) 213
43. Thomas A.W., Cannon A., Bartlett E., Ellis-Jones J., and Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 96 (2005) 1301
44. Rule A.D., Jacobson D.J., McGree M.E., Girman C.J., Lieber M.M., and Jacobsen S.J. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol 174 (2005) 1317
45. McNeill S.A., Hargreave T.B., Geffriaud-Ricouard C., Santoni J., and Roehrborn C.G. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 57 (2001) 459
46. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendam T., and Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319
47. Roehrborn C., Kaplan S., Kraus S.R., Bavendam T., Wang J., and Guan Z. Tolterodine extended release (TER) and/or tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size. Urology 70 suppl. (2007) 158 2007
48. Roehrborn C., Kaplan S., Wang J., Bavendam T., and Guan Z. Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of serum prostate-specific antigen (PSA) level. Urology 70 suppl. (2007) 157 2007
49. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 (2005) 2273
50. Hartung R. Do alpha-blockers prevent the occurrence of acute urinary retention?. Eur Urol 39 suppl. (2001) 13
51. Elbadawi A. Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. I. Symptoms and urodynamics. Urology 51 (1998) 62
52. Roehrborn C.G. 5-Alpha-reductase inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol 5 suppl. (2003) S12
53. Roehrborn C.G. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 97 (2006) 734
54. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 97 suppl. (2006) 12
55. Boyle P., Roehrborn C., Harkaway R., Logie J., de laRosette J., and Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45 (2004) 620